Plexxikon Inc. v. Novartis Pharmaceuticals Corporation

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 PLEXXIKON INC., Case No. 17-cv-04405-HSG Plaintiff, ORDER GRANTING IN PART AND

DENYING IN PART PLAINTIFF’S

v. MOTION IN LIMINE NO. 4 AND

DENYING PLAINTIFF’S MOTION IN

NOVARTIS PHARMACEUTICALS LIMINE NO.

CORPORATION,

Re: Dkt. Nos. 264, 266 Defendant. 12 The Court rules on the pending motions in limine (“MIL”) as detailed below. I. PLAINTIFF’S MIL NO. 4 Plaintiff Plexxikon Inc. moves to preclude Defendant Novartis Pharmaceuticals Corporation from offering certain evidence at trial regarding: (1) Defendant’s claim that it did not willfully infringe the asserted patents; (2) the development and commercialization of Mekinist, a drug that is prescribed and sold in combination with Tafinlar (the accused product); and (3)Defendant’s due diligence in purchasing GSK’s oncology portfolio (which included Tafinlar). See Dkt. No. 264. Plaintiff urges that Defendant withheld information…